APO Research
Talk to an analyst

APO RESEARCH · REPORT

Menstrual Regulating Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Menstrual Regulating Drug Market Analysis and Forecast 2026-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchMenstrual Regulating Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Menstrual Regulating Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Menstrual Regulating Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Menstrual Regulating Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Menstrual Regulating Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Menstrual Regulating Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Menstrual Regulating Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Menstrual Regulating Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Menstrual Regulating Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Menstrual Regulating Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Menstrual Regulating Drug include Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Pfizer Inc., Bayer AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd. and Sandoz International GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Menstrual Regulating Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Menstrual Regulating Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Menstrual Regulating Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Menstrual Regulating Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Menstrual Regulating Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Menstrual Regulating Drug sales, projected growth trends, production technology, application and end-user industry.

Menstrual Regulating Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V.

Pfizer Inc.

Bayer AG

AbbVie Inc.

Sun Pharmaceutical Industries Ltd.

Sandoz International GmbH

Novartis AG

Lupin Limited

HRA Pharma

GlaxoSmithKline plc

Dr. Reddy's Laboratories Ltd.

Allergan plc

Menstrual Regulating Drug Segment by Type

Contraceptive Pills

Non-contraceptive Pills

Menstrual Regulating Drug Segment by Application

Irregular Menstruation

Menstrual Pain

Others

Menstrual Regulating Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Menstrual Regulating Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Menstrual Regulating Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Menstrual Regulating Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Menstrual Regulating Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Menstrual Regulating Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Menstrual Regulating Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Menstrual Regulating Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Contraceptive Pills Major Manufacturers Table 3. Non-contraceptive Pills Major Manufacturers Table 4. Global Menstrual Regulating Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Irregular Menstruation Major Manufacturers Table 6. Menstrual Pain Major Manufacturers Table 7. Others Major Manufacturers Table 8. Menstrual Regulating Drug Industry Trends Table 9. Menstrual Regulating Drug Industry Drivers Table 10. Menstrual Regulating Drug Industry Opportunities and Challenges Table 11. Menstrual Regulating Drug Industry Restraints Table 12. Global Menstrual Regulating Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Menstrual Regulating Drug Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Menstrual Regulating Drug Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2026) Table 16. Global Menstrual Regulating Drug Revenue Market Share by Region (2027-2032) Table 17. Global Menstrual Regulating Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Menstrual Regulating Drug Sales by Region (2021-2026) & (K Units) Table 19. Global Menstrual Regulating Drug Sales by Region (2027-2032) & (K Units) Table 20. Global Menstrual Regulating Drug Sales Market Share by Region (2021-2026) Table 21. Global Menstrual Regulating Drug Sales Market Share by Region (2027-2032) Table 22. Global Menstrual Regulating Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Menstrual Regulating Drug Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Menstrual Regulating Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Menstrual Regulating Drug Sales Market Share by Manufacturers (2021-2026) Table 26. Global Menstrual Regulating Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Menstrual Regulating Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Menstrual Regulating Drug Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Menstrual Regulating Drug Manufacturers, Product Type & Application Table 30. Global Menstrual Regulating Drug Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Menstrual Regulating Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Menstrual Regulating Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2026) Table 37. Global Menstrual Regulating Drug Revenue Market Share by Type (2027-2032) Table 38. Global Menstrual Regulating Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 40. Global Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 41. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2026) Table 42. Global Menstrual Regulating Drug Sales Market Share by Type (2027-2032) Table 43. Global Menstrual Regulating Drug Price by Type (2021-2026) & (US$/Unit) Table 44. Global Menstrual Regulating Drug Price by Type (2027-2032) & (US$/Unit) Table 45. Global Menstrual Regulating Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2026) Table 49. Global Menstrual Regulating Drug Revenue Market Share by Application (2027-2032) Table 50. Global Menstrual Regulating Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 52. Global Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 53. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2026) Table 54. Global Menstrual Regulating Drug Sales Market Share by Application (2027-2032) Table 55. Global Menstrual Regulating Drug Price by Application (2021-2026) & (US$/Unit) Table 56. Global Menstrual Regulating Drug Price by Application (2027-2032) & (US$/Unit) Table 57. Teva Pharmaceutical Industries Ltd. Company Information Table 58. Teva Pharmaceutical Industries Ltd. Business Overview Table 59. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 61. Teva Pharmaceutical Industries Ltd. Recent Development Table 62. Johnson & Johnson Company Information Table 63. Johnson & Johnson Business Overview Table 64. Johnson & Johnson Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Johnson & Johnson Menstrual Regulating Drug Product Portfolio Table 66. Johnson & Johnson Recent Development Table 67. Merck & Co., Inc. Company Information Table 68. Merck & Co., Inc. Business Overview Table 69. Merck & Co., Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio Table 71. Merck & Co., Inc. Recent Development Table 72. Mylan N.V. Company Information Table 73. Mylan N.V. Business Overview Table 74. Mylan N.V. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Mylan N.V. Menstrual Regulating Drug Product Portfolio Table 76. Mylan N.V. Recent Development Table 77. Pfizer Inc. Company Information Table 78. Pfizer Inc. Business Overview Table 79. Pfizer Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Pfizer Inc. Menstrual Regulating Drug Product Portfolio Table 81. Pfizer Inc. Recent Development Table 82. Bayer AG Company Information Table 83. Bayer AG Business Overview Table 84. Bayer AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bayer AG Menstrual Regulating Drug Product Portfolio Table 86. Bayer AG Recent Development Table 87. AbbVie Inc. Company Information Table 88. AbbVie Inc. Business Overview Table 89. AbbVie Inc. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AbbVie Inc. Menstrual Regulating Drug Product Portfolio Table 91. AbbVie Inc. Recent Development Table 92. Sun Pharmaceutical Industries Ltd. Company Information Table 93. Sun Pharmaceutical Industries Ltd. Business Overview Table 94. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 96. Sun Pharmaceutical Industries Ltd. Recent Development Table 97. Sandoz International GmbH Company Information Table 98. Sandoz International GmbH Business Overview Table 99. Sandoz International GmbH Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sandoz International GmbH Menstrual Regulating Drug Product Portfolio Table 101. Sandoz International GmbH Recent Development Table 102. Novartis AG Company Information Table 103. Novartis AG Business Overview Table 104. Novartis AG Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis AG Menstrual Regulating Drug Product Portfolio Table 106. Novartis AG Recent Development Table 107. Lupin Limited Company Information Table 108. Lupin Limited Business Overview Table 109. Lupin Limited Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Lupin Limited Menstrual Regulating Drug Product Portfolio Table 111. Lupin Limited Recent Development Table 112. HRA Pharma Company Information Table 113. HRA Pharma Business Overview Table 114. HRA Pharma Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. HRA Pharma Menstrual Regulating Drug Product Portfolio Table 116. HRA Pharma Recent Development Table 117. GlaxoSmithKline plc Company Information Table 118. GlaxoSmithKline plc Business Overview Table 119. GlaxoSmithKline plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio Table 121. GlaxoSmithKline plc Recent Development Table 122. Dr. Reddy's Laboratories Ltd. Company Information Table 123. Dr. Reddy's Laboratories Ltd. Business Overview Table 124. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio Table 126. Dr. Reddy's Laboratories Ltd. Recent Development Table 127. Allergan plc Company Information Table 128. Allergan plc Business Overview Table 129. Allergan plc Menstrual Regulating Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Allergan plc Menstrual Regulating Drug Product Portfolio Table 131. Allergan plc Recent Development Table 132. North America Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 133. North America Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 134. North America Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 135. North America Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 136. North America Menstrual Regulating Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 137. North America Menstrual Regulating Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 138. North America Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 139. North America Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 140. North America Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 141. North America Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 142. North America Menstrual Regulating Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 143. North America Menstrual Regulating Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 144. North America Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. North America Menstrual Regulating Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 146. North America Menstrual Regulating Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 147. North America Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 148. North America Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 149. North America Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 150. North America Menstrual Regulating Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 151. North America Menstrual Regulating Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 152. United States Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 153. Canada Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 154. Mexico Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 155. Europe Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. Europe Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. Europe Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 158. Europe Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 159. Europe Menstrual Regulating Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 160. Europe Menstrual Regulating Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 161. Europe Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Europe Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Europe Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 164. Europe Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 165. Europe Menstrual Regulating Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 166. Europe Menstrual Regulating Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 167. Europe Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Europe Menstrual Regulating Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 169. Europe Menstrual Regulating Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 170. Europe Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 171. Europe Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 172. Europe Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 173. Europe Menstrual Regulating Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 174. Europe Menstrual Regulating Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 175. Germany Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 176. France Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 177. U.K. Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 178. Italy Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 179. Russia Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 180. Spain Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 181. Netherlands Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 182. Switzerland Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 183. Sweden Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 184. Poland Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 185. China Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 186. China Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 187. China Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 188. China Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 189. China Menstrual Regulating Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 190. China Menstrual Regulating Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 191. China Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 192. China Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 193. China Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 194. China Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 195. China Menstrual Regulating Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 196. China Menstrual Regulating Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 197. Asia Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 198. Asia Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 199. Asia Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 200. Asia Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 201. Asia Menstrual Regulating Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 202. Asia Menstrual Regulating Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 203. Asia Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 204. Asia Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 205. Asia Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 206. Asia Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 207. Asia Menstrual Regulating Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 208. Asia Menstrual Regulating Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 209. Asia Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 210. Asia Menstrual Regulating Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 211. Asia Menstrual Regulating Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 212. Asia Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 213. Asia Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 214. Asia Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 215. Asia Menstrual Regulating Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 216. Asia Menstrual Regulating Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 217. Japan Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 218. South Korea Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 219. India Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 220. Australia Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 221. Taiwan Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 222. Southeast Asia Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 223. SAMEA Menstrual Regulating Drug Revenue by Type (2021-2026) & (US$ Million) Table 224. SAMEA Menstrual Regulating Drug Revenue by Type (2027-2032) & (US$ Million) Table 225. SAMEA Menstrual Regulating Drug Sales by Type (2021-2026) & (K Units) Table 226. SAMEA Menstrual Regulating Drug Sales by Type (2027-2032) & (K Units) Table 227. SAMEA Menstrual Regulating Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 228. SAMEA Menstrual Regulating Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 229. SAMEA Menstrual Regulating Drug Revenue by Application (2021-2026) & (US$ Million) Table 230. SAMEA Menstrual Regulating Drug Revenue by Application (2027-2032) & (US$ Million) Table 231. SAMEA Menstrual Regulating Drug Sales by Application (2021-2026) & (K Units) Table 232. SAMEA Menstrual Regulating Drug Sales by Application (2027-2032) & (K Units) Table 233. SAMEA Menstrual Regulating Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 234. SAMEA Menstrual Regulating Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 235. SAMEA Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 236. SAMEA Menstrual Regulating Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 237. SAMEA Menstrual Regulating Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 238. SAMEA Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 239. SAMEA Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 240. SAMEA Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 241. SAMEA Menstrual Regulating Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 242. SAMEA Menstrual Regulating Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 243. Brazil Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 244. Argentina Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 245. Chile Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 246. Colombia Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 247. Peru Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 248. Saudi Arabia Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 249. Israel Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 250. UAE Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 251. Turkey Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 252. Iran Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 253. Egypt Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Table 254. Key Raw Materials Table 255. Raw Materials Key Suppliers Table 256. Menstrual Regulating Drug Distributors List Table 257. Menstrual Regulating Drug Customers List Table 258. Research Programs/Design for This Report Table 259. Authors List of This Report Table 260. Secondary Sources Table 261. Primary Sources List of Figures Figure 1. Menstrual Regulating Drug Image Figure 2. Global Menstrual Regulating Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Menstrual Regulating Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Contraceptive Pills Image Figure 5. Non-contraceptive Pills Image Figure 6. Global Menstrual Regulating Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Menstrual Regulating Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Irregular Menstruation Image Figure 9. Menstrual Pain Image Figure 10. Others Image Figure 11. Global Menstrual Regulating Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Menstrual Regulating Drug Revenue (2021-2032) & (US$ Million) Figure 13. Global Menstrual Regulating Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Menstrual Regulating Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2032) Figure 16. Global Menstrual Regulating Drug Sales (2021-2032) & (K Units) Figure 17. Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Menstrual Regulating Drug Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Menstrual Regulating Drug Sales YoY (2021-2032) & (K Units) Figure 20. Europe Menstrual Regulating Drug Sales YoY (2021-2032) & (K Units) Figure 21. China Menstrual Regulating Drug Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Menstrual Regulating Drug Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Menstrual Regulating Drug Sales YoY (2021-2032) & (K Units) Figure 24. Global Menstrual Regulating Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Menstrual Regulating Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Menstrual Regulating Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Menstrual Regulating Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032) Figure 30. Global Menstrual Regulating Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Menstrual Regulating Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032) Figure 33. Global Menstrual Regulating Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Menstrual Regulating Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032) Figure 36. Global Menstrual Regulating Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Menstrual Regulating Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032) Figure 39. North America Menstrual Regulating Drug Revenue Share by Type (2021-2032) Figure 40. North America Menstrual Regulating Drug Sales Share by Type (2021-2032) Figure 41. North America Menstrual Regulating Drug Revenue Share by Application (2021-2032) Figure 42. North America Menstrual Regulating Drug Sales Share by Application (2021-2032) Figure 43. North America Menstrual Regulating Drug Revenue Share by Country (2021-2032) Figure 44. North America Menstrual Regulating Drug Sales Share by Country (2021-2032) Figure 45. Europe Menstrual Regulating Drug Revenue Share by Type (2021-2032) Figure 46. Europe Menstrual Regulating Drug Sales Share by Type (2021-2032) Figure 47. Europe Menstrual Regulating Drug Revenue Share by Application (2021-2032) Figure 48. Europe Menstrual Regulating Drug Sales Share by Application (2021-2032) Figure 49. Europe Menstrual Regulating Drug Revenue Share by Country (2021-2032) Figure 50. Europe Menstrual Regulating Drug Sales Share by Country (2021-2032) Figure 51. China Menstrual Regulating Drug Revenue Share by Type (2021-2032) Figure 52. China Menstrual Regulating Drug Sales Share by Type (2021-2032) Figure 53. China Menstrual Regulating Drug Revenue Share by Application (2021-2032) Figure 54. China Menstrual Regulating Drug Sales Share by Application (2021-2032) Figure 55. Asia Menstrual Regulating Drug Revenue Share by Type (2021-2032) Figure 56. Asia Menstrual Regulating Drug Sales Share by Type (2021-2032) Figure 57. Asia Menstrual Regulating Drug Revenue Share by Application (2021-2032) Figure 58. Asia Menstrual Regulating Drug Sales Share by Application (2021-2032) Figure 59. Asia Menstrual Regulating Drug Revenue Share by Country (2021-2032) Figure 60. Asia Menstrual Regulating Drug Sales Share by Country (2021-2032) Figure 61. SAMEA Menstrual Regulating Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Menstrual Regulating Drug Sales Share by Type (2021-2032) Figure 63. SAMEA Menstrual Regulating Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA Menstrual Regulating Drug Sales Share by Application (2021-2032) Figure 65. SAMEA Menstrual Regulating Drug Revenue Share by Country (2021-2032) Figure 66. SAMEA Menstrual Regulating Drug Sales Share by Country (2021-2032) Figure 67. Menstrual Regulating Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Menstrual Regulating Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Contraceptive Pills
  • Non-contraceptive Pills
Applications
  • Irregular Menstruation
  • Menstrual Pain
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Novartis AG
  • Lupin Limited
  • HRA Pharma
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Menstrual Regulating Drug Market by Type
  3. 1.2.1 Global Menstrual Regulating Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Contraceptive Pills
  5. 1.2.3 Non-contraceptive Pills
  6. 1.3 Menstrual Regulating Drug Market by Application
  7. 1.3.1 Global Menstrual Regulating Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Irregular Menstruation
  9. 1.3.3 Menstrual Pain
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Menstrual Regulating Drug Market Dynamics
  1. 2.1 Menstrual Regulating Drug Industry Trends
  2. 2.2 Menstrual Regulating Drug Industry Drivers
  3. 2.3 Menstrual Regulating Drug Industry Opportunities and Challenges
  4. 2.4 Menstrual Regulating Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Menstrual Regulating Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Menstrual Regulating Drug Revenue by Region
  3. 3.2.1 Global Menstrual Regulating Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Menstrual Regulating Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Menstrual Regulating Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Menstrual Regulating Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Menstrual Regulating Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Menstrual Regulating Drug Sales by Region
  9. 3.4.1 Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Menstrual Regulating Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Menstrual Regulating Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Menstrual Regulating Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Menstrual Regulating Drug Revenue by Manufacturers
  2. 4.1.1 Global Menstrual Regulating Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Menstrual Regulating Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Menstrual Regulating Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Menstrual Regulating Drug Sales by Manufacturers
  6. 4.2.1 Global Menstrual Regulating Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Menstrual Regulating Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Menstrual Regulating Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Menstrual Regulating Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Menstrual Regulating Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Menstrual Regulating Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Menstrual Regulating Drug Manufacturers, Product Type & Application
  13. 4.7 Global Menstrual Regulating Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Menstrual Regulating Drug Market CR5 and HHI
  16. 4.8.2 2025 Menstrual Regulating Drug Tier 1, Tier 2, and Tier 3
5 Menstrual Regulating Drug Market by Type
  1. 5.1 Global Menstrual Regulating Drug Revenue by Type
  2. 5.1.1 Global Menstrual Regulating Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Menstrual Regulating Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Menstrual Regulating Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Menstrual Regulating Drug Sales by Type
  6. 5.2.1 Global Menstrual Regulating Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Menstrual Regulating Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Menstrual Regulating Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Menstrual Regulating Drug Price by Type
6 Menstrual Regulating Drug Market by Application
  1. 6.1 Global Menstrual Regulating Drug Revenue by Application
  2. 6.1.1 Global Menstrual Regulating Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Menstrual Regulating Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Menstrual Regulating Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Menstrual Regulating Drug Sales by Application
  6. 6.2.1 Global Menstrual Regulating Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Menstrual Regulating Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Menstrual Regulating Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Menstrual Regulating Drug Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd.
  2. 7.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Menstrual Regulating Drug Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Merck & Co., Inc.
  14. 7.3.1 Merck & Co., Inc. Company Information
  15. 7.3.2 Merck & Co., Inc. Business Overview
  16. 7.3.3 Merck & Co., Inc. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio
  18. 7.3.5 Merck & Co., Inc. Recent Developments
  19. 7.4 Mylan N.V.
  20. 7.4.1 Mylan N.V. Company Information
  21. 7.4.2 Mylan N.V. Business Overview
  22. 7.4.3 Mylan N.V. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Mylan N.V. Menstrual Regulating Drug Product Portfolio
  24. 7.4.5 Mylan N.V. Recent Developments
  25. 7.5 Pfizer Inc.
  26. 7.5.1 Pfizer Inc. Company Information
  27. 7.5.2 Pfizer Inc. Business Overview
  28. 7.5.3 Pfizer Inc. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Inc. Menstrual Regulating Drug Product Portfolio
  30. 7.5.5 Pfizer Inc. Recent Developments
  31. 7.6 Bayer AG
  32. 7.6.1 Bayer AG Company Information
  33. 7.6.2 Bayer AG Business Overview
  34. 7.6.3 Bayer AG Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bayer AG Menstrual Regulating Drug Product Portfolio
  36. 7.6.5 Bayer AG Recent Developments
  37. 7.7 AbbVie Inc.
  38. 7.7.1 AbbVie Inc. Company Information
  39. 7.7.2 AbbVie Inc. Business Overview
  40. 7.7.3 AbbVie Inc. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Inc. Menstrual Regulating Drug Product Portfolio
  42. 7.7.5 AbbVie Inc. Recent Developments
  43. 7.8 Sun Pharmaceutical Industries Ltd.
  44. 7.8.1 Sun Pharmaceutical Industries Ltd. Company Information
  45. 7.8.2 Sun Pharmaceutical Industries Ltd. Business Overview
  46. 7.8.3 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  48. 7.8.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  49. 7.9 Sandoz International GmbH
  50. 7.9.1 Sandoz International GmbH Company Information
  51. 7.9.2 Sandoz International GmbH Business Overview
  52. 7.9.3 Sandoz International GmbH Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Sandoz International GmbH Menstrual Regulating Drug Product Portfolio
  54. 7.9.5 Sandoz International GmbH Recent Developments
  55. 7.10 Novartis AG
  56. 7.10.1 Novartis AG Company Information
  57. 7.10.2 Novartis AG Business Overview
  58. 7.10.3 Novartis AG Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Novartis AG Menstrual Regulating Drug Product Portfolio
  60. 7.10.5 Novartis AG Recent Developments
  61. 7.11 Lupin Limited
  62. 7.11.1 Lupin Limited Company Information
  63. 7.11.2 Lupin Limited Business Overview
  64. 7.11.3 Lupin Limited Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Lupin Limited Menstrual Regulating Drug Product Portfolio
  66. 7.11.5 Lupin Limited Recent Developments
  67. 7.12 HRA Pharma
  68. 7.12.1 HRA Pharma Company Information
  69. 7.12.2 HRA Pharma Business Overview
  70. 7.12.3 HRA Pharma Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 HRA Pharma Menstrual Regulating Drug Product Portfolio
  72. 7.12.5 HRA Pharma Recent Developments
  73. 7.13 GlaxoSmithKline plc
  74. 7.13.1 GlaxoSmithKline plc Company Information
  75. 7.13.2 GlaxoSmithKline plc Business Overview
  76. 7.13.3 GlaxoSmithKline plc Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio
  78. 7.13.5 GlaxoSmithKline plc Recent Developments
  79. 7.14 Dr. Reddy's Laboratories Ltd.
  80. 7.14.1 Dr. Reddy's Laboratories Ltd. Company Information
  81. 7.14.2 Dr. Reddy's Laboratories Ltd. Business Overview
  82. 7.14.3 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio
  84. 7.14.5 Dr. Reddy's Laboratories Ltd. Recent Developments
  85. 7.15 Allergan plc
  86. 7.15.1 Allergan plc Company Information
  87. 7.15.2 Allergan plc Business Overview
  88. 7.15.3 Allergan plc Menstrual Regulating Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Allergan plc Menstrual Regulating Drug Product Portfolio
  90. 7.15.5 Allergan plc Recent Developments
8 North America
  1. 8.1 North America Menstrual Regulating Drug Market Size by Type
  2. 8.1.1 North America Menstrual Regulating Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Menstrual Regulating Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Menstrual Regulating Drug Price by Type (2021-2032)
  5. 8.2 North America Menstrual Regulating Drug Market Size by Application
  6. 8.2.1 North America Menstrual Regulating Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Menstrual Regulating Drug Price by Application (2021-2032)
  9. 8.3 North America Menstrual Regulating Drug Market Size by Country
  10. 8.3.1 North America Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Menstrual Regulating Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Menstrual Regulating Drug Market Size by Type
  2. 9.1.1 Europe Menstrual Regulating Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Menstrual Regulating Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Menstrual Regulating Drug Price by Type (2021-2032)
  5. 9.2 Europe Menstrual Regulating Drug Market Size by Application
  6. 9.2.1 Europe Menstrual Regulating Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Menstrual Regulating Drug Price by Application (2021-2032)
  9. 9.3 Europe Menstrual Regulating Drug Market Size by Country
  10. 9.3.1 Europe Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Menstrual Regulating Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Menstrual Regulating Drug Market Size by Type
  2. 10.1.1 China Menstrual Regulating Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Menstrual Regulating Drug Sales by Type (2021-2032)
  4. 10.1.3 China Menstrual Regulating Drug Price by Type (2021-2032)
  5. 10.2 China Menstrual Regulating Drug Market Size by Application
  6. 10.2.1 China Menstrual Regulating Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 10.2.3 China Menstrual Regulating Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Menstrual Regulating Drug Market Size by Type
  2. 11.1.1 Asia Menstrual Regulating Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Menstrual Regulating Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Menstrual Regulating Drug Price by Type (2021-2032)
  5. 11.2 Asia Menstrual Regulating Drug Market Size by Application
  6. 11.2.1 Asia Menstrual Regulating Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Menstrual Regulating Drug Price by Application (2021-2032)
  9. 11.3 Asia Menstrual Regulating Drug Market Size by Country
  10. 11.3.1 Asia Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Menstrual Regulating Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Menstrual Regulating Drug Market Size by Type
  2. 12.1.1 SAMEA Menstrual Regulating Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Menstrual Regulating Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Menstrual Regulating Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Menstrual Regulating Drug Market Size by Application
  6. 12.2.1 SAMEA Menstrual Regulating Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Menstrual Regulating Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Menstrual Regulating Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Menstrual Regulating Drug Market Size by Country
  10. 12.3.1 SAMEA Menstrual Regulating Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Menstrual Regulating Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Menstrual Regulating Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Menstrual Regulating Drug Value Chain Analysis
  2. 13.1.1 Menstrual Regulating Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Menstrual Regulating Drug Production Mode & Process
  6. 13.2 Menstrual Regulating Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Menstrual Regulating Drug Distributors
  9. 13.2.3 Menstrual Regulating Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst